Hechi

Researchers are comparing the safety and effectiveness of two intravenous drugs, urokinase and alteplase, in treating acute ischemic stroke AIS within 6 hours of symptom onset. Alteplase is currently recommended within 4.5 hours but is costly, while urokinase is less expensive. Existing studies show mixed results for urokinase, so this study aims to gather real-world data on both treatments, including safety, effectiveness, and economic impact, to help inform future stroke care. The study involves patients receiving either intravenous urokinase or alteplase as treatment for AIS. Researchers will observe and analyze these treatments in multiple centers across the nation, comparing outcomes and exploring different urokinase dosages and related risk factors. Alteplase serves as the active control group to evaluate urokinase against current standards. Participants will be monitored for their functional recovery using the modified Rankin scale at 90 days after treatment to assess good outcomes. The study includes clinical diagnosis confirmation, imaging to exclude hemorrhage, and patient consent procedures. Data on safety, effectiveness, and costs will be collected, with follow-up assessments at day 90. The trial aims to provide comprehensive information over its duration until December 2026.